Loading clinical trials...
Loading clinical trials...
Safety and Immunogenicity of GSK's Rabies G SAM (CNE) Vaccine [GSK3903133A] in Healthy Adults.
Conditions
Interventions
Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)
+4 more
Locations
4
United States
GSK Investigational Site
South Miami, Florida, United States
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Baltimore, Maryland, United States
GSK Investigational Site
Rochester, New York, United States
Start Date
August 13, 2019
Primary Completion Date
July 28, 2021
Completion Date
July 1, 2022
Last Updated
March 1, 2024
NCT06779175
NCT05284097
NCT04772469
NCT06113757
NCT05321433
NCT03110770
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions